Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Comparative Review of Pharmacological Treatment Guidelines for Bipolar Disorder

양극성 장애의 약물치료 가이드라인 비교

  • Seoyeon Chin (Department of Food and Nutrition, Duksung Women's University) ;
  • Hyoyoung Kim (College of Pharmacy, Duksung Women's University) ;
  • Yesul Kim (College of Pharmacy, Duksung Women's University) ;
  • ;
  • Bo-young Kwon (College of Pharmacy, Duksung Women's University) ;
  • Boyoon Choi (College of Pharmacy, Duksung Women's University) ;
  • Bobae Lee (College of Pharmacy, Duksung Women's University) ;
  • Jiye Lee (College of Pharmacy, Duksung Women's University) ;
  • Chae-Eun Kwon (College of Pharmacy, Duksung Women's University) ;
  • Yeongdo Mun (College of Pharmacy, Duksung Women's University) ;
  • Kaveesha Fernando (College of Pharmacy, Duksung Women's University) ;
  • Ji Hyun Park (College of Pharmacy, Duksung Women's University)
  • 진서연 (덕성여자대학교 식품영양학과) ;
  • 김효영 (덕성여자대학교 약학과) ;
  • 김예슬 (덕성여자대학교 약학과) ;
  • 허채원 (덕성여자대학교 약학과) ;
  • 권보영 (덕성여자대학교 약학과) ;
  • 최보윤 (덕성여자대학교 약학과) ;
  • 이보배 (덕성여자대학교 약학과) ;
  • 이지예 (덕성여자대학교 약학과) ;
  • 권채은 (덕성여자대학교 약학과) ;
  • 문영도 (덕성여자대학교 약학과) ;
  • ;
  • 박지현 (덕성여자대학교 약학과)
  • Received : 2023.09.04
  • Accepted : 2023.09.20
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Bipolar disorder displays a spectrum of manifestations, including manic, hypomanic, depressive, mixed, psychotic, and atypical episodes, contributing to its chronic nature and association with heightened suicide risk. Creating effective pharmacotherapy guidelines is crucial for managing bipolar disorder and reducing its prevalence. Treatment algorithms grounded in science have improved symptom management, but variations in recommended medications arise from research differences, healthcare policies, and cultural nuances globally. Methods: This study compares Korea's bipolar disorder treatment algorithm with guidelines from the UK, Australia, and an international association. The aim is to uncover disparities in key recommended medications and their underlying factors. Differences in CYP450 genotypes affecting drug metabolism contribute to distinct recommended medications. Variances also stem from diverse guideline development approaches-expert consensus versus metaanalysis results-forming the primary differences between Korea and other countries. Results: Discrepancies remain in international guidelines relying on meta-analyses due to timing and utilized studies. Drug approval speeds further impact medication selection. However, limited high-quality research results are the main cause of guideline variations, hampering consistent treatment conclusions. Conclusion: Korea's unique Delphi-based treatment algorithm stands out. To improve evidence-based recommendations, large-scale studies assessing bipolar disorder treatments for the Korean population are necessary. This foundation will ensure future recommendations are rooted in scientific evidence.

Keywords

Acknowledgement

본 논문은 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구이다(No. 2021R1G1A10952511321082086810103).

References

  1. Bahk WM, et al. Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary. Clin Psychopharmacol Neurosci. 2022;20(4):747-61. https://doi.org/10.9758/cpn.2022.20.4.747
  2. Kwak KP. Bipolar Disorder. Journal of the Korean Medical Association 2007;50:348.
  3. Kim SJ. Pharmacological Treatment Strategies for Acute Bipolar Depression. J Korean Neuropsychiatr Assoc 2018; 57(4):287-300. https://doi.org/10.4306/jknpa.2018.57.4.287
  4. Health Insurance Review and Assessment S. 'Bipolar disorder' with severe mood swings, 40% of middle-aged people in their 40s and 50s. Available from https://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=531&CONT_SEQ=334226. Accessed August 14, 2023.
  5. Cerimele MJ, Fortney CJ, and Unutzer J. Bipolar Disorder and Population Health. Psychiatric Services 2017;68(2):192-4. https://doi.org/10.1176/appi.ps.201600011
  6. Kim W, et al. Korean Medication Algorithm Project for Bipolar Disorder 2022: Overview. J Korean Neuropsychiatr Assoc 2022;61(2):98-109. https://doi.org/10.4306/jknpa.2022.61.2.98
  7. American Psychiatric A. Diagnostic and statistical manual of mental disorders : DSM-5, 5th ed. Arlington VA. 2013.
  8. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016;30(6):495-553. https://doi.org/10.1177/0269881116636545
  9. National Collaborating Centre for Mental H, National Institute for Health and Care Excellence: Clinical Guidelines, in Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. London: The British Psychological Society and The Royal College of Psychiatrists, 2014.
  10. Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20(2):97-170. https://doi.org/10.1111/bdi.12609
  11. Malhi GS, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry 2021;55(1):7-117.
  12. Fountoulakis KN, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017;20(2):180-95.
  13. Jeong JH, et al. Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines. Clin Psychopharmacol Neurosci 2023;21(1):32-48. https://doi.org/10.9758/cpn.2023.21.1.32
  14. Korean College of Clinical P. Clinical Pharmacology, Seoul, Shin-il Books, 2022.
  15. Shah N, Grover S, and Rao GP. Clinical Practice Guidelines for Management of Bipolar Disorder. Indian J Psychiatry 2017;59(Suppl 1):S51-S66. https://doi.org/10.4103/0019-5545.196974
  16. Woo YS and Bahk W-M. Recent advances in the pharmacotherapy of psychiatric disorders. jkma 2011;54(10):1061-9. https://doi.org/10.5124/jkma.2011.54.10.1061
  17. Jeong JH, et al. Korean Medication Algorithm Project for Bipolar Disorder 2022: Rapid Cycling. J Korean Neuropsychiatr Assoc 2022;61(3):204-13. https://doi.org/10.4306/jknpa.2022.61.3.204
  18. Konstantinou G, et al. Repetitive transcranial magnetic stimulation (rTMS) in bipolar disorder: A systematic review. Bipolar Disorders 2022;24(1):10-26. https://doi.org/10.1111/bdi.13099
  19. Lin SK. Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on East Asians. Journal of Personalized Medicine 2022;12(9):1362.
  20. Zhang X, et al. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics 2019;44(2):163-73. https://doi.org/10.1111/jcpt.12780
  21. Koopmans AB, et al. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Translational Psychiatry 2021;11(1):141.
  22. Veldic M, et al. Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Frontiers in Pharmacology 2019;10:83.
  23. Berk M, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64(6):468-75. https://doi.org/10.1016/j.biopsych.2008.04.022